

Application No. 08/960,557

Docket No.: 50454-56103USCIP

REMARKS

Claims 29, 30, 32-36, 38-42, and 44-61 are pending. Claim 29 has been amended to delete "without causing treatment limiting hepatotoxicity, elevations in uric acid, or glucose levels such that use of said formulation is discontinued" and correct a typographical error. Claim 35 has been amended to correct a typographical error. Claim 47 has been amended to delete "without causing treatment limiting hepatotoxicity, elevations in uric acid, or glucose levels such that use of said formulation is discontinued."

Amendments to the specification

The paragraphs beginning at page 3, line 25 and page 44, line 1 have been amended to correct typographical errors. The table beginning at page 42 has been amended to correct typographical errors.

No new matter has been added by these amendments.

Amendments to Figure 5

Replacement Figure 5 is submitted herewith to correct typographical errors. Specifically, the third bar from the left has been amended to recite "32.7%" instead of "37.9%" and the fourth bar from the left has been amended to recite "67.3%" instead of "62.1%." No new matter is added by these amendments.

Conclusion

Favorable consideration and allowance of this application are respectfully requested.

Dated: March 12, 2007

Respectfully submitted,

By 

Paul M. Zagar

Registration No.: 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant